Marché mondial du traitement de l'adrénoleucodystrophie - Tendances et prévisions du secteur jusqu'en 2029

Analyse et perspectives du marché mondial du traitement de l'adrénoleucodystrophie

Le marché du traitement de l'adrénoleucodystrophie devrait connaître une croissance de marché de 10,25 % au cours de la période de prévision de 2022 à 2029. Le rapport de Data Bridge Market Research sur le marché du traitement de l'adrénoleucodystrophie fournit une analyse et des informations sur les différents facteurs qui devraient prévaloir tout au long de la période de prévision tout en fournissant leurs impacts sur la croissance du marché. L'augmentation de la prévalence des maladies chroniques à l'échelle mondiale accélère la croissance du marché du traitement de l'adrénoleucodystrophie.

L'adrénoleucodystrophie est une maladie génétique rare qui provoque l'accumulation d'acides gras à longue chaîne (AGTLC) dans le cerveau. L'ALD est provoquée par une mutation du gène ABCD1 sur le chromosome X. Les trois types d'adrénoleucodystrophie comprennent l'adrénomyélopathie, l'ALD cérébrale infantile et la maladie d'Addison. On sait que l'ALD cérébrale infantile progresse rapidement chez les enfants âgés de 3 à 10 ans.

L'augmentation du nombre de nourrissons souffrant d'adrénoleucodystrophie dans le monde est l'un des principaux facteurs de croissance du marché du traitement de l'adrénoleucodystrophie. L'augmentation de la demande de médicaments ciblés pour traiter les complications causées par la mutation génétique et l'augmentation du soutien financier aux chercheurs pour développer de nouvelles interventions accélèrent la croissance du marché. L'augmentation du nombre de fusions et de collaborations entre fabricants pour traiter l'ALD et l'augmentation du nombre de programmes de recherche et développement influencent davantage le marché. En outre, le développement technologique , l'augmentation des dépenses de santé , l'augmentation de la prévalence des troubles génétiques et la croissance démographique ont un effet positif sur le marché du traitement de l'adrénoleucodystrophie. En outre, l'accès des patients s'en trouve amélioré et les opportunités rentables offertes aux acteurs du marché au cours de la période de prévision de 2022 à 2029 s'en trouvent ainsi étendues.

On the other hand, side-effects associated with stem cell therapy and corticosteroid replacement therapy are expected to obstruct the market growth. The stringent regulations are projected to challenge the adrenoleukodystrophy treatment market in the forecast period of 2022-2029.

This adrenoleukodystrophy treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info adrenoleukodystrophy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Adrenoleukodystrophy Treatment Market Scope and Market Size

The adrenoleukodystrophy treatment market is segmented on the basis of types, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of types, the adrenoleukodystrophy treatment market is segmented into childhood cerebral Adrenoleukodystrophy (ccALD), adrenomyelopathy, Addison’s disease and others.
• The treatment segment for adrenoleukodystrophy treatment market includes medication, gene therapy, bone marrow transplantation and others.
• On the basis of route of administration, adrenoleukodystrophy treatment market is segmented into oral and parenterals.
• Based on end-user, the adrenoleukodystrophy treatment market is segmented into hospitals, homecare, specialty clinics and others
• Adrenoleukodystrophy treatment market has also been segmented based on the distribution channel into hospital, pharmacy, online pharmacy, retail pharmacy and others.

Adrenoleukodystrophy Treatment Market Country Level Analysis

The adrenoleukodystrophy treatment market is analyzed and market size information is provided by country, types, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global adrenoleukodystrophy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the adrenoleukodystrophy treatment market due to the well-established healthcare infrastructure and presence of key market players within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the rise in awareness about rare diseases in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The adrenoleukodystrophy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Adrenoleukodystrophy Treatment Market Share Analysis

The adrenoleukodystrophy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related adrenoleukodystrophy treatment market.

Français Certains des principaux acteurs opérant dans le rapport sur le marché du traitement de l'adrénoleucodystrophie sont bluebird bio, Inc., Orpheris, Inc., MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer Inc., Amgen Inc., AstraZeneca, Abbott, agtc, ReceptoPharm, Inc., The Myelin Project, SOM Biotech SL, Viking Therapeutics, Nutra Pharma Corporation, Genetix Biotech Asia Pvt. Ltd., Magenta Therapeutics, NeuroVia, Inc., Novartis AG, CELGENE CORPORATION, Jazz Pharmaceuticals, Inc. et Sanofi, entre autres.

SKU-50726